Make better decisions with better MRD testing
Unmatched sensitivity and specificity for confident MRD detection. Interested in learning more about using Haystack MRD™?
MRD testing
See what other tests can't
Haystack Oncology uses the next generation of circulating tumor DNA (ctDNA) detection technology to see through the noise and uncover residual, recurrent, and resistant disease earlier than any other minimal residual disease (MRD) test.
Haystack MRD
Haystack MRD
MRD testing demands the most sensitive ctDNA detection. The Haystack MRD Test is a tumor-informed ctDNA test that is specifically designed for post-surgical MRD applications.
Residual disease detection
Go beyond standard risk assessment for adjuvant chemotherapy guidance to ensure that the right person gets the right treatment.
Treatment response monitoring
Disease recurrence surveillance
Detect molecular recurrence with greater lead time before clinical relapse.
Haystack MRD
Dive Deeper
Haystack Oncology was founded to dramatically improve patient outcomes by optimizing treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing better MRD testing for better clinical management and therapeutic development.
The Difference
Why choose Haystack MRD?
Analytical superiority
Transformative technology
Built by giants
Haystack Oncology was founded by pioneers in blood-based diagnostics who were the first to envision a revolution in patient care made possible by groundbreaking molecular methods.
News & Events
The Latest
Find out what's happening at Haystack Oncology and stay up-to-date with industry news.
American Association for Cancer Research 2024
Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 202 ...
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus’ TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™).